Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats

Journal of Immunology

Volumn 180, Issue 4, 2008, Pages 2294-2298

  Tawara, Tomonori ^a,b   Hasegawa, Kazumasa ^a   Sugiura, Yusuke ^a   Harada, Katsuhiko ^a   Miura, Toru ^a   Hayashi, Sunao ^a   Tahara, Tomoyuki ^a   Ishikawa, Masaharu ^a   Yoshida, Hideaki ^a   Kubo, Kinya ^a   Ishida, Isao ^a   Kataoka, Shiro ^a,b  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTIBODY; COBROTOXIN; HD8 ANTIBODY; HLA DR ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; LYSINE; MONOCLONAL ANTIBODY; PROLINE; SERINE; UNCLASSIFIED DRUG; ALLOANTIBODY; ANTINEOPLASTIC AGENT; COMPLEMENT; IMMUNOGLOBULIN FC FRAGMENT;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEDIATED CYTOTOXICITY; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT SYSTEM; CONTROLLED STUDY; FRAGMENTATION REACTION; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INFUSION; MALE; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RAT; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL LINE; CHO CELL; CONGENIC STRAIN; CRICETULUS; GENETICS; HAMSTER; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MACACA; METABOLISM; MORTALITY; MOUSE MUTANT; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANIMALS, CONGENIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CHO CELLS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; CRICETINAE; CRICETULUS; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; INFUSIONS, INTRAVENOUS; ISOANTIBODIES; LYMPHOMA; MACACA FASCICULARIS; MALE; MICE; MICE, SCID; RATS; TRANSPLANTATION, HETEROLOGOUS;

EID: 42149090514     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.4.2294     Document Type: Article

References (28)

1. Dillman, R. O. 1999. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 18: 465-471.
2. van der Kolk, L. E., A. J. Grillo-Lopez, J. W. Baars, C. E. Hack, and H. van Oers, M. 2001. Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol. 115: 807-811.
3. Buysmann, S., C. E. Hack, N. van Diepen, F. J. Surachno, and I. J. ten Berge. 1997. Administration of OKT3 as a two-hour infusion attenuates first-dose side effects. Transplantation 64: 1620-1623.
4. Chatenoud, L., C. Ferran, A. Reuter, C. Legendre, Y. Gevaert, H. Kreis, P. Franchimont, and J. F. Bach. 1989. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-γ. N. Engl. J. Med. 320: 1420-1421.
5. Ferran, C., K. Sheehan, M. Dy, R. Schreiber, S. Merite, P. Landais, L. H. Noel, G. Grau, J. Bluestone, J. F. Bach, and L. Chatenoud. 1990. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol. 20: 509-515.
6. Raasveld, M. H., F. J. Bemelman, P. T. Schellekens, N. van Diepen, F. A. van Dongen, A. van Royen, E. C. E. Hack, and I. J. ten Berge. 1993. Complement activation during OKT3 treatment: a possible explanation for respiratory side effects. Kidney Int. 43: 1140-1149.
7. Jensen, M., U. Winkler, O. Manzke, V. Diehl, and A. Engert. 1998. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann. Hematol. 77: 89-91.
8. Byrd, J. C., J. K. Waselenko, T. J. Maneatis, T. Murphy, F. T. Ward, B. P. Monahan, M. A. Sipe, S. Donegan, and C. A. White. 1999. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J. Clin. Oncol. 17: 791-795.
9. Winkler, U., M. Jensen, O. Manzke, H. Schulz, V. Diehl, and A. Engert. 1999. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94: 2217-2224.
10. Bemelman, F. J., S. Buysmann, J. Surachno, J. M. Wilmink, P. T. Schellekens, and I. J. ten Berge. 1994. Pretreatment with divided doses of steroids strongly decreases side effects of OKT3. Kidney Int. 46: 1674-1679.
11. Shi, J. D., C. Bullock, W. C. Hall, V. Wescott, H. Wang, D. J. Levitt, and C. K. Klingbeil. 2002. In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells. Leuk. Lymphoma 43: 1303-1312.
12. Klingbeil, C., and D. H. Hsu. 1999. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use. Toxicol. Pathol. 27: 1-3.
13. Lin, T. S., W. Stock, M. S. Lucas, P. Porcu, V. V. Abhyankar, S. K. Jefferson, B. Briggs, H. Wang, C. Cheney, I. W. Flinn, et al. 2002. A phase I dose escalation study of apolizumab (Hu1D10) using a stepped up dosing schedule in patients with chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL). Blood 100: 807a.
14. Nagy, Z. A., B. Hubner, C. Lohning, R. Rauchenberger, S. Reiffert, E. Thomassen-Wolf, S. Zahn, S. Leyer, E. M. Schier, A. Zahradnik, et al. 2002. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat. Med. 8: 801-807.
15. Tawara, T., K. Hasegawa, Y. Sugiura, T. Tahara, I. Ishida, and S. Kataoka. 2007. Fully human antibody exhibits pan-human leukocyte antigen-DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas. Cancer Sci. 98: 921-928.
16. Ishida, I., K. Tomizuka, H. Yoshida, T. Tahara, N. Takahashi, A. Ohguma, S. Tanaka, M. Umehashi, H. Maeda, C. Nozaki, et al. 2002. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells. 4: 91-102.
17. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeler. 1991. Sequences of Proteins of Immunological Interest. No. 91-3242. U. S. Public Health Services, National Institutes of Health, Bethesda.
18. Vogel, C. W., D. C. Fritzinger, B. E. Hew, M. Thorne, and H. Bammert. 2004. Recombinant cobra venom factor. Mol. Immunol. 41: 191-199.
19. Tao, M. H., R. I. Smith, and S. L. Morrison. 1993. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J. Exp. Med. 178: 661-667.
20. Xu, Y., R. Oomen, and M. H. Klein. 1994. Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement. J. Biol. Chem. 269: 3469-3474.
21. Sondermann, P., R. Huber, V. Oosthuizen, and U. Jacob. 2000. The 3.2-A crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 406: 267-273.
22. Chen, J., J. B. Anderson, C. DeWeese Scott, N. D. Fedorova, L. Y. Geer, S. He, D. I. Hurwitz, J. D. Jackson, A. R. Jacobs, C. J. Lanczycki, et al. 2003. MMDB: Entrez's 3D-structure database. Nucleic Acids Res. 31: 474-477.
23. Cartron, G., L. Dacheux, G. Salles, P. Solal Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99: 754-758.
24. Weng, W. K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21: 3940-3947.
25. Jefferis, R., J. Pound, J. Lund, and M. Goodall. 1994. Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects. Ann. Biol. Clin. 52: 57-65.
26. Idusogie, E. E., L. G. Presta, H. Gazzano-Santoro, K. Totpal, P. Y. Wong, M. Ultsch, Y. G. Meng, and M. G. Mulkerrin. 2000. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164: 4178-4184.
27. Idusogie, E. E., P. Y. Wong, L. G. Presta, H. Gazzano-Santoro, K. Totpal, M. Ultsch, and M. G. Mulkerrin. 2001. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166: 2571-2575.
28. Dimitriadou, V., S. Mecheri, M. Koutsilieris, W. Fraser, R. Al-Daccak, and W. Mourad. 1998. Expression of functional major histocompatibility complex class II molecules on HMC-1 human mast cells. J. Leukocyte Biol. 64: 791-799.